Combined Use of Tocilizumab and Mesenchymal Stromal Cells in the Treatment of Severe Covid-19: Case Report.
Cell Transplant
; 30: 9636897211021008, 2021.
Article
in English
| MEDLINE | ID: covidwho-1255859
ABSTRACT
The coronavirus pandemic is one of the most significant public health events in recent history. Currently, no specific treatment is available. Some drugs and cell-based therapy have been tested as alternatives to decrease the disease's symptoms, length of hospital stay, and mortality. We reported the case of a patient with a severe manifestation of COVID-19 in critical condition who did not respond to the standard procedures used, including six liters of O2 supplementation under a nasal catheter and treatment with dexamethasone and enoxaparin in prophylactic dose. The patient was treated with tocilizumab and an advanced therapy product based on umbilical cord-derived mesenchymal stromal cells (UC-MSC). The combination of tocilizumab and UC-MSC proved to be safe, with no adverse effects, and the results of this case report prove to be a promising alternative in the treatment of patients with severe acute respiratory syndrome due to SARS-CoV-2.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Mesenchymal Stem Cell Transplantation
/
Antibodies, Monoclonal, Humanized
/
COVID-19
Type of study:
Case report
/
Prognostic study
Limits:
Humans
/
Middle aged
Language:
English
Journal:
Cell Transplant
Journal subject:
Transplantation
Year:
2021
Document Type:
Article
Affiliation country:
09636897211021008
Similar
MEDLINE
...
LILACS
LIS